+ Watch VRML
on My Watchlist
When CAPS gives me the chance to red thumb Vermillion, I don't wait until I have time to review the latest news. I take my red thumb and deal with the short-term consequences, because I'm fairly confident that the business model is unsustainable. The company can only come close to breaking even every Q4 when they book "true-up" royalties on OVA1 from Quest, and otherwise their story is a choppy decline in cash and share price. Weakness in the VASCLIR clinical data has only emphasized the company's position as a one-hit wonder. Every once in a while the stock gets manipulated upward for a short-term spike on some bogus PR, but the downward drift resumes very quickly afterwards. With only 8M in cash at the end of 2012, Vermillion will have to pull a new magic trick to remain liquid until the end of 2013.
TMF Stock Spam. Garbage.
Current testing for ovarian cancer, when a mass is detected, is just slightly better than a coin flip. An ovary's fate compares to a tonsil's in the sixties. With the price of gasoline blowing past $4 a gallon and escalating "greens fees" at the country club, most gynecologic oncologists will have to start doing elective plastic surgery on the side, once Vermillion's OVA1 test becomes the new standard.
One of the best buys for 2011, existing OVA1 product has double digit growth quarter on quarter. New PAD test will generate hype sometimes in the middle of the year. You get existing business and hype, best of both worlds.
They have several patents on a global bases. OVAR1 for ovarian cancer, and they just received one for PAD. The stock price has been up to $34 and I am sure it will go well beyond $34 on this run.
Fremont ,CA & Diagnostic Substances could get some attention after end of year tax dip.
Ovarian cancer drug maker.Coverage initiated by Wedbush - Outperform - Target $1052 Week Range $0.04 - $34Short Interest Days to Cover - 7.88
If I said about Bonton that their financials are horrible, then Vermillion is ten times worse.Cash barely covers accounts payables, in addition debt of 10M and around 250M in negative earnings with market cap of 114M?Motto - "Your health, our passion." - Sorry VRML, this is about business right now.If I was a seer - then I don't foresee much success for this company in the future.
VRML, Vermillion, Inc. (Other OTC: VRML.PK)June 18th, 2010Last Price: $13.5052wk Range: 0.01 - 34.00VRML is a molecular diagnostics company based in Fremont, California.Announced just recently the European Patent Office has issued a Decision to Grant patent number 1,493,741 entitled "Use of Biomarkers for Detecting Ovarian Cancer" to the Company.The patent claims are directed to biomarker combinations for the diagnosis and management of ovarian cancer and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.Check out the Year to Date chart below to see the growth spread since Mid September 2009.About VRMLVermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.Find out more about VRML at their website: www.vermillion.com
To add to knnryerye insight about this company:On Oct 9 they received some cash on a warrant deal.It sounds that they may have received some encouraging news from the FDA (Kiss of Death).Stock price shoots up on speculation that they may have a real drug to sell to another company.Reality kicks in and the mountain begins to look like an iceberg.Cracks begin to form and it looks like a big piece is about to fall off.It was probably burning all the new cash which started the melt down.Botton line: knnryerye was right, this is a speculative bet on gravity.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions